pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Bispecific Antibody · news · pharmadog
← back to Bispecific Antibody
News · Bispecific Antibody
285
stories
3d
AbbVie grooves with DISCO’s solid tumor tech in up to $2.5B licensing deal
biospace
3d
Ramping up: 3 biotechs growing their workforce after series C raises
biospace
4d
AbbVie busts a move with Disco in $2.5B dance aimed at bispecific discovery
fiercebiotech
4d
Summit’s rejection, Isomorphic’s record $5B raise, obesity and Alzheimer’s in the spotlight
biospace
4d
5 acquisitions that forced Big Pharmas to co-parent
biospace
5d
FDA letter rejecting Summit cancer drug cites ‘modest’ benefit in data compared with toxicity risk
endpoints
5d
FDA’s complete response letter for Summit’s ivonescimab cites China-heavy data beyond survival miss
fiercebiotech
6d
Summit shares fall as FDA rejects closely watched PD-1/VEGF drug
biopharma dive
6d
J&J pays $2.2B upfront for Ollin, taps Blackstone to fund eye disease trial
biospace
6d
Biogen inks $411M neurodegeneration pact with protein degrader biotech TrimTech
fiercebiotech
6d
J&J pays $2.2B upfront for Ollin to challenge Roche’s Vabysmo with phase 3 bispecific
fiercebiotech
6d
Aclaris drops TSLP program from pipeline after flunking phase 2 eczema test
fiercebiotech
7d
Summit's PD-1xVEGF rejected by FDA in lung cancer
biospace
9d
FDA rejects Summit’s ivonescimab, derailing US arrival of much-hyped PD-1xVEGF class
fiercebiotech
9d
Sanofi-backed Windward hits $225M IPO goal, as Rezera delays listing over ‘market conditions’
fiercebiotech
9d
Windward prices $175M IPO to advance China-licensed lung drugs
biopharma dive
10d
Chutes & Ladders—Bristol Myers' research chief out amid R&D reorganization
fiercebiotech
11d
Novartis’ Zolgensma woes, BIO’s China plan, GLP-1s’ new safety warning, FDA’s stacked November
biospace
11d
BioNTech pays $205M for FDA voucher to speed up ‘late-stage oncology pipeline’
fiercebiotech
11d
China has a clear shot to 2030 goals, though economic, cultural barriers remain
biospace
12d
Coherus shrinks headcount 30% to narrow focus of cancer combo
fiercebiotech
13d
Sanofi-backed Windward breezes toward $204M IPO to fund respiratory pipeline from China
fiercebiotech
16d
#SITC26: Immunocore reports early data for brenetafusp plus Kimmtrak in uveal melanoma
endpoints
16d
Verdicts for Summit/Akeso, Capricor, Vertex mark FDA’s stacked November
biospace
16d
Merck abandons Sutro-partnered IL-2 drug in ‘routine pipeline prioritization’
fiercebiotech
17d
At ASH, drugmakers to showcase early data for three-pronged cancer therapies
biopharma dive
17d
T-time: British biotech pours $133M into the pot for bispecifics
biospace
17d
T-Therapeutics reloads with a $133M megaround for bispecifics
biopharma dive
18d
Boehringer bets big on China, offering $7B biobucks for Sino cancer programs
biospace
18d
6 potential blockbusters that could pave China’s path to 2030 ambitions
biospace
← prev
page 1 of 10
next →